An observational study in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Novartis Pharmaceuticals. Recruiting at 14 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hemoglobinuria, Paroxysmal by Novartis — 5 open to participants now, 7 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Novartis.
Among the 16 studies in Hemoglobinuria, Paroxysmal by Novartis, this one is one of 4 that started in 2025, is one of 7 observational ones, and was the 11th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 48 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →5 of the 16 studies in Hemoglobinuria, Paroxysmal by Novartis are open now, in 8 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 18–99
Novartis Pharmaceuticals · Sites in Italy
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 3 more countries
Ages 2–18
Novartis Pharmaceuticals · Sites in United States
Ages 18–99
By country, each count listing its studies:
Of the 29 Hemoglobinuria, Paroxysmal studies recruiting now, 13 (45%) set no upper age limit and 11 (38%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 80 is below the median of 90 across 37 observational studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 28 across the 8 interventional studies, 80 across the 7 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
2 of the studies in Hemoglobinuria, Paroxysmal by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT06931691Novartis PharmaceuticalsA Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China | 2027-04-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Hemoglobinuria, Paroxysmal by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The implementation of new standards for the management of PNH and the use of iptacopan in patients with PNH are expected to change the treatment landscape and improve the overall prognosis of patients.
Based on these backgrounds, we plan to conduct a real-world study of iptacopan to further evaluate its impact on treatment-related outcomes, disease management, and healthcare resource utilization in Chinese patients with PNH.
Adult PNH patients receiving iptacopan for the first time, including those who are complement inhibitor naive and treated
Inclusion criteria For Cohort 1,
Patient who meets all the following criteria can be included in this study:
For Cohort 2,
Patient who meets all the following criteria can be included in this study:
For Cohort 1 and Cohort 2, patients who meet any of the following criteria will meet the exclusion criteria for this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PNH patients with a confirmed diagnosis of PNH in the medical record and who had never received complement inhibitor therapy (complement inhibitor naive patients)
Drug: LNP023
PNH patients with a confirmed diagnosis of PNH in the medical record who had been treated with a stable dose of a C5 complement inhibitor (e.g., eculizumab) for at least 3 months (C5i-treated patients; this cohort will be only start enrollment after the indication for iptacopan is to be approved in China).
Drug: LNP023
Capsules for oral administration
Also known as: Iptacopan Hydrochloride
Change from baseline in hemoglobin (Hb) levels at designated time points
Assessment of the Hematological Response to iptacopan.
Time frame: Baseline, 12 months
Number of participants having Hb normalization (Hb level ≥ 12 g/dL) after iptacopan initiation.
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: 12 months
Duration of Hb level ≥ 12 g/dL within a 12-month
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: 12 months
Change from baseline in LDH Levels after iptacopan initiation
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: Baseline, 12 Months
Number of participants with LDH levels ≤ 1.5 x ULN before vs. after iptacopan initiation
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: 12 months
Number of participants having LDH normalization before and after iptacopan initiation
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: 12 monhts
Duration of LDH level ≤ 1.5 x ULN within 12 months
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: 12 months
Change from baseline in ARC Levels after iptacopan initiation
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: Baseline, 12 monhts
Number of participants having ARC normalization before and after iptacopan initiation
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: Baseline, 12 months
Change from baseline in bilirubin after iptacopan initiation
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: Baseline, 12 months
Number of participants with hepatosplenomegaly before and after iptacopan initiation
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: Baseline, 12 months
Number of participants with a positive coomb's test after iptacopan initiation
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: 12 months
Number of participants with PNH related signs or symptoms before and after iptacopan treatment
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: Baseline, 12 months
Change from baseline in PNH clone value
Change from baseline in flow cytometry results to assess the impact of iptacopan on Treatment-Related Outcomes.
Time frame: Baseline, 12 months
Rate, reasons (complement activation conditions (CAC), missed doses, etc.), duration, and interventions for breakthrough hemolysis (BTH)
Assessing the Impact of iptacopan on Treatment-Related Outcomes
Time frame: 12 months
Change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale after iptacopan initiation
FACIT is a 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function to assess the Impact of iptacopan on Treatment-Related Outcomes. The minimum value is 0 and maximum value is 52, and higher scores mean a worse outcome.
Time frame: Baseline, 12 months
Work Productivity and Activity Impairment Questionnaire-Specific Health Problems (WPAI-SHP) at each visit, change from baseline in WPAI-SHP after iptacopan initiation
WPAI-SHP is a tool used to measure the impact of health problems on work productivity and regular activities. The scale includes several components. Absenteeism: This measures the percentage of work time missed due to a specific health problem. Presenteeism: This measures the percentage of impairment while working due to the health problem. Work productivity loss: This combines absenteeism and presenteeism to measure overall work impairment. Activity impairment: This measures the percentage of impairment in regular activities due to the health problem. The scores are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, which means worse outcomes.
Time frame: Baseline, 12 months
Adverse events (AEs) and Serious adverse events (SAEs) occurring during treatment with iptacopan
Assessing the safety of iptacopan
Time frame: 12 monhts
Treatment regimen for PNH 12 months before iptacopan treatment; reasons of discontinuation of previous complement inhibitor;
Assessing the impact of iptacopan on disease management
Time frame: Baseline
Use of concomitant medications (e.g., corticosteroids, androgen, immunosuppressants, anti-coagulants, etc.) for PNH and PNH-related complications (e.g. thrombosis, renal failure, etc.) before and after iptacopan treatment;
Assessing the impact of iptacopan on disease management
Time frame: Baseline, 12 months
Duration of iptacopan treatment, reasons for discontinuation, switching to other treatments, proportion of patients who switch from iptacopan to other treatments;
Assessing the impact of iptacopan on disease management
Time frame: 12 monhts
Number of participants with blood transfusion before and after iptacopan treatment, duration and number of units of blood transfusion due to BTH
Assessing the impact of iptacopan on disease management
Time frame: Baseline, 12 months
Number of participants hospitalized, outpatient, emergency room and intensive care unit (ICU) visits related to PNH
Assessing the impact of iptacopan on healthcare resource utilization
Time frame: 12 monhts
Length of inpatient stay related to PNH
Assessing the impact of iptacopan on healthcare resource utilization
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.